| 1 |
34461632 | Bortezomib and rituximab in de novo adolescent/adult CD20-positive, Ph-negative pre-B-cell acute lymphoblastic leukemia. | 2021 Sep 14 |
1 |
| 2 |
32685310 | An Advanced AIDS Patient With CD4 <20 and Plasmablastic Lymphoma Achieving Complete Response With the V-EPOCH Regimen. | 2020 Jun 15 |
1 |
| 3 |
28232617 | Humoral Compensation after Bortezomib Treatment of Allosensitized Recipients. | 2017 Jul |
1 |
| 4 |
28367758 | Bortezomib as a Novel Approach to Early Recurrent Membranous Glomerulonephritis After Kidney Transplant Refractory to Combined Conventional Rituximab Therapy. | 2017 Jun |
1 |
| 5 |
27980307 | Genetic and Epigenetic Modulation of CD20 Expression in B-Cell Malignancies: Molecular Mechanisms and Significance to Rituximab Resistance. | 2016 |
1 |
| 6 |
24528507 | CD20-positive plasmablastic lymphoma with excellent response to bortezomib combined with rituximab. | 2014 Jul |
1 |
| 7 |
23305345 | Overcoming bortezomib resistance in human B cells by anti-CD20/rituximab-mediated complement-dependent cytotoxicity and epoxyketone-based irreversible proteasome inhibitors. | 2013 Jan 10 |
3 |
| 8 |
23927993 | t(11;14) multiple myeloma: a subtype associated with distinct immunological features, immunophenotypic characteristics but divergent outcome. | 2013 Oct |
2 |
| 9 |
20200358 | Bortezomib modulates surface CD20 in B-cell malignancies and affects rituximab-mediated complement-dependent cytotoxicity. | 2010 May 6 |
4 |
| 10 |
20574159 | Proteolytic pathways involved in modulation of CD20 levels. | 2010 Aug |
1 |